Fate Therapeutics (FATE) EBIT Margin (2012 - 2026)
Fate Therapeutics' (FATE) quarterly EBIT Margin came in at 2540.42% in Q1 2026, down 635.0% YoY from 474.84% in Q1 2025, and little changed on a QoQ basis from 2536.23% in Q4 2025.
Powered by 
Analysis
Fate Therapeutics (FATE) EBIT Margin (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 14 years of EBIT Margin data on file, last reported at 2540.42% in Q1 2026.
- Quarterly EBIT Margin fell 635.0% year-over-year to 2540.42% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2207.47% (down 70400.0% YoY) and the FY2025 annual result came in at 2222.45%, down 67982.0% from the prior year.
- EBIT Margin held at 2540.42% in Q1 2026, from 2536.23% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 48.48% in Q1 2023 to a low of 6705.79% in Q2 2023.
- A 5-year average of 1983.62% and a median of 1995.12% in 2025 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2023 — EBIT Margin plunged 625774 bps — and 2024, when it soared 604006 bps.
- Tracing FATE's EBIT Margin over 5 years: stood at 145.23% in 2022, then slumped by 1875 bps to 2868.44% in 2023, then fell by 16 bps to 3319.78% in 2024, then grew by 24 bps to 2536.23% in 2025, then fell by 0 bps to 2540.42% in 2026.
- The last three EBIT Margin figures came in at 2540.42% (Q1 2026), 2536.23% (Q4 2025), and 1995.12% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Fate Therapeutics | 299.79 Mn | 299.79 Mn | - | -1,495.39% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,495.39% |
| Mar 31, 2026 | -2,540.42% |
| Dec 31, 2025 | -2,536.23% |
| Sep 30, 2025 | -1,995.12% |
| Jun 30, 2025 | -1,938.54% |
| Mar 31, 2025 | -2,534.07% |
| Dec 31, 2024 | -3,319.78% |
| Sep 30, 2024 | -1,703.87% |
| Jun 30, 2024 | -665.73% |
| Mar 31, 2024 | -2,652.88% |
| Dec 31, 2023 | -2,868.44% |
| Sep 30, 2023 | -2,637.81% |
| Jun 30, 2023 | -6,705.79% |
| Mar 31, 2023 | -48.48% |
| Dec 31, 2022 | -145.23% |
| Sep 30, 2022 | -576.67% |
| Jun 30, 2022 | -448.05% |
| Mar 31, 2022 | -404.40% |
| Dec 31, 2021 | -406.48% |
| Sep 30, 2021 | -383.99% |